This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | MicrobiomeTrials
← Back to trials NCT05186753
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2022-06-27Est. Completion: 2025-05-22
Enrollment target: 237 participantsLocations University of Alabama at Birmingham, Birmingham, Alabama, United States Mayo Clinic Arizona, Phoenix, Arizona, United States One of a Kind Clinical Research Center, Scottsdale, Arizona, United States Modena Allergy and Asthma Clinical, La Jolla, California, United States Innovative Research of West Florida, Clearwater, Florida, United States Mayo Clinic - Jacksonville, Jacksonville, Florida, United States University of South Florida, Tampa, Florida, United States Emory University, Atlanta, Georgia, United States Rush University, Chicago, Illinois, United States Walter Reed National Military Medical Center, Bethesda, Maryland, United States Allervie Clinical Research, Glenn Dale, Maryland, United States Institute for Asthma and Allergy, Wheaton, Maryland, United States Brigham and Women's Hospital, Boston, Massachusetts, United States Dana Farber Cancer Institute, Boston, Massachusetts, United States University of Michigan, Ann Arbor, Michigan, United States Washington University at St. Louis, St Louis, Missouri, United States Other microbiome trials you might be interested in Recurrent Breast Carcinoma Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treat…
Mobile, United States Est. completion Nov 6, 2020
Non-small Cell Lung Cancer
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Duke University, Raleigh, North Carolina, United States
University of Cincinnati, Cincinnati, Ohio, United States
The Ohio State University, Columbus, Ohio, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
AIR Care, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Metrodora Institute of Technology, West Valley City, Utah, United States
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Antwerp University Hospital (UZA), Edegem, Belgium
CHU Tivoli, La Louvière, Belgium
Tom Baker Cancer Centre, Calgary, Alberta, Canada
University of Alberta, Edmonton, Alberta, Canada
St. Michael's Hospital, Toronto, Ontario, Canada
Fakultni nemocnice Kralovske Vinohrady, Prague, Czechia
AP-HP- Hopital Pitie-Salpetriere, Paris, France
CHU de Toulouse - Hopital Larrey, Toulouse, France
Universitaetsklinikum Aachen, AoeR, Aachen, Germany
Charité Universitätsmedizin Berlin, Berlin, Germany
Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
Universitätsklinikum Schleswig-Holstein, Kiel, Germany
University Medical Centre Mannheim, Mannheim, Germany
Cork University Hospital, Cork, Ireland
St. James's Hospital, Dublin, Ireland
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna, Italy
AOU Policlinico Rodolico San Marco, Catania, Italy
Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
AUSL della Romagna-Ospedale S.Maria delle Croci, Ravenna, Italy
University Medical Center Groningen, Groningen, Netherlands
Erasmus Rotterdam, Rotterdam, Netherlands
Oslo University Hospital, Oslo, Norway
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdansk, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1 - Klinika Hematoonkologii i Transplantacji Szpiku, Lublin, Poland
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Spain
Hospital Universitario Ramon y Cajal, Madrid, Spain
Instituto de Estudios de Mastocitosis de Castilla La Mancha-Hospital Virgen del Valle, Toledo, Spain
University Hospital Basel, Basel, Switzerland
Guy's Hospital, London, United Kingdom This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participa…
Bakersfield, United States Est. completion Jan 24, 2028
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients …
Birmingham, United States Est. completion Dec 31, 2026